Five-alpha-reductase expression in benign and malignant urothelium: Correlation with disease characteristics and outcome

Daniel A. Barocas, Hideki Kawamoto, David F. Dreizin, Marion E. Howard, Judy Choi, W. Reid Pitts, Xueke You, Satish K. Tickoo, Stephen A. Boorjian, Douglas S. Scherr

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objectives. To evaluate 5-alpha-reductase (5αR) expression in benign and malignant urothelium and to assess the relationship between 5αR expression and tumor stage, tumor grade, and clinical outcome in patients with urothelial carcinoma/transitional cell carcinoma. Methods. We performed immunohistochemistry for 5αR on 53 urothelial specimens from 36 patients with transitional cell carcinoma treated at our institution between June 2002 and July 2003. For each tumor and the adjacent nontumor urothelium, a semiquantitative staining score was calculated. We used t tests and analysis of variance to compare the staining score across groups. Kaplan-Meier and logistic regression analyses were performed to assess the relationship between 5αR expression and clinical outcome. Results. 5αR was expressed throughout the non-neoplastic urothelium. Nontumor urothelium had greater mean staining scores than did tumor specimens (160.1 versus 105.5, P <0.01). Low staining scores were associated with high grade (P <0.05), Stage pT3, pT4, and pTis (P <0.05), and disease progression (P <0.05). A staining score less than the median was a risk factor for progression (odds ratio 6.2, P <0.01) on univariate regression analysis. Patients with a staining score less than the median had a greater likelihood of disease progression (log-rank P <0.05) and cause-specific mortality (log-rank P <0.05). Conclusions. We demonstrated 5αR expression in human urothelium and found that expression is decreased in transitional cell carcinoma in relation to tumor grade and stage. Decreased 5αR expression was associated with disease progression and cause-specific mortality.

Original languageEnglish (US)
Pages (from-to)1134-1139
Number of pages6
JournalUrology
Volume66
Issue number5
DOIs
StatePublished - Nov 2005
Externally publishedYes

Fingerprint

Cholestenone 5 alpha-Reductase
Urothelium
Oxidoreductases
Staining and Labeling
Transitional Cell Carcinoma
Disease Progression
Neoplasms
Regression Analysis
Mortality
Analysis of Variance
Logistic Models
Immunohistochemistry
Odds Ratio
Carcinoma

ASJC Scopus subject areas

  • Urology

Cite this

Barocas, D. A., Kawamoto, H., Dreizin, D. F., Howard, M. E., Choi, J., Pitts, W. R., ... Scherr, D. S. (2005). Five-alpha-reductase expression in benign and malignant urothelium: Correlation with disease characteristics and outcome. Urology, 66(5), 1134-1139. https://doi.org/10.1016/j.urology.2005.06.079

Five-alpha-reductase expression in benign and malignant urothelium : Correlation with disease characteristics and outcome. / Barocas, Daniel A.; Kawamoto, Hideki; Dreizin, David F.; Howard, Marion E.; Choi, Judy; Pitts, W. Reid; You, Xueke; Tickoo, Satish K.; Boorjian, Stephen A.; Scherr, Douglas S.

In: Urology, Vol. 66, No. 5, 11.2005, p. 1134-1139.

Research output: Contribution to journalArticle

Barocas, DA, Kawamoto, H, Dreizin, DF, Howard, ME, Choi, J, Pitts, WR, You, X, Tickoo, SK, Boorjian, SA & Scherr, DS 2005, 'Five-alpha-reductase expression in benign and malignant urothelium: Correlation with disease characteristics and outcome', Urology, vol. 66, no. 5, pp. 1134-1139. https://doi.org/10.1016/j.urology.2005.06.079
Barocas, Daniel A. ; Kawamoto, Hideki ; Dreizin, David F. ; Howard, Marion E. ; Choi, Judy ; Pitts, W. Reid ; You, Xueke ; Tickoo, Satish K. ; Boorjian, Stephen A. ; Scherr, Douglas S. / Five-alpha-reductase expression in benign and malignant urothelium : Correlation with disease characteristics and outcome. In: Urology. 2005 ; Vol. 66, No. 5. pp. 1134-1139.
@article{be3a3f97a2e84e43adf638994fffbb77,
title = "Five-alpha-reductase expression in benign and malignant urothelium: Correlation with disease characteristics and outcome",
abstract = "Objectives. To evaluate 5-alpha-reductase (5αR) expression in benign and malignant urothelium and to assess the relationship between 5αR expression and tumor stage, tumor grade, and clinical outcome in patients with urothelial carcinoma/transitional cell carcinoma. Methods. We performed immunohistochemistry for 5αR on 53 urothelial specimens from 36 patients with transitional cell carcinoma treated at our institution between June 2002 and July 2003. For each tumor and the adjacent nontumor urothelium, a semiquantitative staining score was calculated. We used t tests and analysis of variance to compare the staining score across groups. Kaplan-Meier and logistic regression analyses were performed to assess the relationship between 5αR expression and clinical outcome. Results. 5αR was expressed throughout the non-neoplastic urothelium. Nontumor urothelium had greater mean staining scores than did tumor specimens (160.1 versus 105.5, P <0.01). Low staining scores were associated with high grade (P <0.05), Stage pT3, pT4, and pTis (P <0.05), and disease progression (P <0.05). A staining score less than the median was a risk factor for progression (odds ratio 6.2, P <0.01) on univariate regression analysis. Patients with a staining score less than the median had a greater likelihood of disease progression (log-rank P <0.05) and cause-specific mortality (log-rank P <0.05). Conclusions. We demonstrated 5αR expression in human urothelium and found that expression is decreased in transitional cell carcinoma in relation to tumor grade and stage. Decreased 5αR expression was associated with disease progression and cause-specific mortality.",
author = "Barocas, {Daniel A.} and Hideki Kawamoto and Dreizin, {David F.} and Howard, {Marion E.} and Judy Choi and Pitts, {W. Reid} and Xueke You and Tickoo, {Satish K.} and Boorjian, {Stephen A.} and Scherr, {Douglas S.}",
year = "2005",
month = "11",
doi = "10.1016/j.urology.2005.06.079",
language = "English (US)",
volume = "66",
pages = "1134--1139",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Five-alpha-reductase expression in benign and malignant urothelium

T2 - Correlation with disease characteristics and outcome

AU - Barocas, Daniel A.

AU - Kawamoto, Hideki

AU - Dreizin, David F.

AU - Howard, Marion E.

AU - Choi, Judy

AU - Pitts, W. Reid

AU - You, Xueke

AU - Tickoo, Satish K.

AU - Boorjian, Stephen A.

AU - Scherr, Douglas S.

PY - 2005/11

Y1 - 2005/11

N2 - Objectives. To evaluate 5-alpha-reductase (5αR) expression in benign and malignant urothelium and to assess the relationship between 5αR expression and tumor stage, tumor grade, and clinical outcome in patients with urothelial carcinoma/transitional cell carcinoma. Methods. We performed immunohistochemistry for 5αR on 53 urothelial specimens from 36 patients with transitional cell carcinoma treated at our institution between June 2002 and July 2003. For each tumor and the adjacent nontumor urothelium, a semiquantitative staining score was calculated. We used t tests and analysis of variance to compare the staining score across groups. Kaplan-Meier and logistic regression analyses were performed to assess the relationship between 5αR expression and clinical outcome. Results. 5αR was expressed throughout the non-neoplastic urothelium. Nontumor urothelium had greater mean staining scores than did tumor specimens (160.1 versus 105.5, P <0.01). Low staining scores were associated with high grade (P <0.05), Stage pT3, pT4, and pTis (P <0.05), and disease progression (P <0.05). A staining score less than the median was a risk factor for progression (odds ratio 6.2, P <0.01) on univariate regression analysis. Patients with a staining score less than the median had a greater likelihood of disease progression (log-rank P <0.05) and cause-specific mortality (log-rank P <0.05). Conclusions. We demonstrated 5αR expression in human urothelium and found that expression is decreased in transitional cell carcinoma in relation to tumor grade and stage. Decreased 5αR expression was associated with disease progression and cause-specific mortality.

AB - Objectives. To evaluate 5-alpha-reductase (5αR) expression in benign and malignant urothelium and to assess the relationship between 5αR expression and tumor stage, tumor grade, and clinical outcome in patients with urothelial carcinoma/transitional cell carcinoma. Methods. We performed immunohistochemistry for 5αR on 53 urothelial specimens from 36 patients with transitional cell carcinoma treated at our institution between June 2002 and July 2003. For each tumor and the adjacent nontumor urothelium, a semiquantitative staining score was calculated. We used t tests and analysis of variance to compare the staining score across groups. Kaplan-Meier and logistic regression analyses were performed to assess the relationship between 5αR expression and clinical outcome. Results. 5αR was expressed throughout the non-neoplastic urothelium. Nontumor urothelium had greater mean staining scores than did tumor specimens (160.1 versus 105.5, P <0.01). Low staining scores were associated with high grade (P <0.05), Stage pT3, pT4, and pTis (P <0.05), and disease progression (P <0.05). A staining score less than the median was a risk factor for progression (odds ratio 6.2, P <0.01) on univariate regression analysis. Patients with a staining score less than the median had a greater likelihood of disease progression (log-rank P <0.05) and cause-specific mortality (log-rank P <0.05). Conclusions. We demonstrated 5αR expression in human urothelium and found that expression is decreased in transitional cell carcinoma in relation to tumor grade and stage. Decreased 5αR expression was associated with disease progression and cause-specific mortality.

UR - http://www.scopus.com/inward/record.url?scp=27744435388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744435388&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2005.06.079

DO - 10.1016/j.urology.2005.06.079

M3 - Article

C2 - 16286153

AN - SCOPUS:27744435388

VL - 66

SP - 1134

EP - 1139

JO - Urology

JF - Urology

SN - 0090-4295

IS - 5

ER -